» Articles » PMID: 22348039

Aberrant Expression of Proteins Involved in Signal Transduction and DNA Repair Pathways in Lung Cancer and Their Association with Clinical Parameters

Abstract

Background: Because cell signaling and cell metabolic pathways are executed through proteins, protein signatures in primary tumors are useful for identifying key nodes in signaling networks whose alteration is associated with malignancy and/or clinical outcomes. This study aimed to determine protein signatures in primary lung cancer tissues.

Methodology/ Principal Findings: We analyzed 126 proteins and/or protein phosphorylation sites in case-matched normal and tumor samples from 101 lung cancer patients with reverse-phase protein array (RPPA) assay. The results showed that 18 molecules were significantly different (p<0.05) by at least 30% between normal and tumor tissues. Most of those molecules play roles in cell proliferation, DNA repair, signal transduction and lipid metabolism, or function as cell surface/matrix proteins. We also validated RPPA results by Western blot and/or immunohistochemical analyses for some of those molecules. Statistical analyses showed that Ku80 levels were significantly higher in tumors of nonsmokers than in those of smokers. Cyclin B1 levels were significantly overexpressed in poorly differentiated tumors while Cox2 levels were significantly overexpressed in neuroendocrinal tumors. A high level of Stat5 is associated with favorable survival outcome for patients treated with surgery.

Conclusions/ Significance: Our results revealed that some molecules involved in DNA damage/repair, signal transductions, lipid metabolism, and cell proliferation were drastically aberrant in lung cancer tissues, and Stat5 may serve a molecular marker for prognosis of lung cancers.

Citing Articles

Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo.

Zhang X, Zhang R, Ren C, Xu Y, Wu S, Meng C Blood Adv. 2021; 6(3):891-901.

PMID: 34861697 PMC: 8945299. DOI: 10.1182/bloodadvances.2021006156.


KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations.

Zhang X, Zhang R, Chen H, Wang L, Ren C, Pataer A Am J Cancer Res. 2021; 10(12):4464-4475.

PMID: 33415011 PMC: 7783771.


Role of the JAK/STAT Pathway in Cervical Cancer: Its Relationship with HPV E6/E7 Oncoproteins.

Gutierrez-Hoya A, Soto-Cruz I Cells. 2020; 9(10).

PMID: 33076315 PMC: 7602614. DOI: 10.3390/cells9102297.


Gene expression and prognosis of insulin‑like growth factor‑binding protein family members in non‑small cell lung cancer.

Wang J, Hu Z, Li D, Xu J, Zeng Z Oncol Rep. 2019; 42(5):1981-1995.

PMID: 31545451 PMC: 6787967. DOI: 10.3892/or.2019.7314.


Serum anti-GAPDH autoantibody levels reflect the severity of cervical lesions: A potential serum biomarker for cervical cancer screening.

Xu M, Kim H, Kim S, Ju W, Kim Y, Chang K Oncol Lett. 2019; 18(1):255-264.

PMID: 31289495 PMC: 6539791. DOI: 10.3892/ol.2019.10326.


References
1.
Sultan A, Xie J, LeBaron M, Ealley E, Nevalainen M, Rui H . Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene. 2004; 24(5):746-60. DOI: 10.1038/sj.onc.1208203. View

2.
Khuri F, Wu H, Lee J, Kemp B, Lotan R, Lippman S . Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res. 2001; 7(4):861-7. View

3.
Jiang H, Reinhardt H, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H . The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 2009; 23(16):1895-909. PMC: 2725944. DOI: 10.1101/gad.1815309. View

4.
Hsiao J, Jin Y, Tsai S, Shiau A, Wu C, Su W . Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer. 2003; 89(2):344-9. PMC: 2394270. DOI: 10.1038/sj.bjc.6601003. View

5.
Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F . A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-61. PMC: 1413718. DOI: 10.1073/pnas.0510565103. View